Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism

Endocrine. 2024 Apr;84(1):245-252. doi: 10.1007/s12020-023-03627-w. Epub 2023 Dec 12.

Abstract

Objective: Aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA) are the most common subtypes of primary aldosteronism (PA), and the PA subtype dictates the treatment options. This study aimed to identify predictors of declined estimated glomerular filtration rate (eGFR) following each treatment in patients with APA and IHA.

Methods: We retrospectively investigated 45 patients with APA who had undergone adrenalectomy (ADX) and 37 patients with IHA who had received treatment with a mineralocorticoid receptor antagonist (MRA) to identify pre-treatment risk factors for eGFR decline during the post-treatment follow-up period.

Results: Patients with APA who underwent ADX exhibited higher eGFR declines than patients with IHA treated with MRA at the 6-month post-treatment evaluation point. A high preoperative plasma aldosterone concentration (PAC) in patients with APA and a high body mass index (BMI) in patients with IHA were identified as independent predictors of higher eGFR decline at 6 months post-treatment (β=0.42 and β=0.36, respectively). In patients with APA, the cutoff PAC to best predict a 20% decrease in eGFR following ADX, as determined by receiver operating characteristic analysis, was 524 pg/mL. In patients with IHA, the cutoff BMI to best predict a 10% decrease in eGFR following MRA administration was 25.3 kg/m2. In addition, lower preoperative flow-mediated vasodilation was associated with eGFR decline after ADX in patients with APA.

Conclusions: Greater attention should be given to the above-mentioned risk factors to prevent renal impairment following each treatment in patients with both APA and IHA.

Keywords: body mass index; eGFR; flow-mediated vasodilation.

MeSH terms

  • Adenoma* / complications
  • Aldosterone
  • Humans
  • Hyperaldosteronism* / complications
  • Hyperaldosteronism* / drug therapy
  • Hyperaldosteronism* / surgery
  • Hypertension* / complications
  • Kidney Diseases* / complications
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Retrospective Studies
  • Risk Factors

Substances

  • Aldosterone
  • Mineralocorticoid Receptor Antagonists